Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL 1102 in relapsing-remitting multiple sclerosis
2006-004736-79Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Oct 2006
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing ATL 1102 with Placebo (2 arms). Primary endpoint: Cumulative number of new active MRI lesions. Started Oct 2006; status: completed.
02
Drugs
avicursen
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-004736-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004736-79.